Abstract
Editorials1 July 1985Management of Myelodysplastic SyndromesRICHARD A. LARSON, M.D.RICHARD A. LARSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-1-136 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by anemia, neutropenia, or thrombocytopenia in various combinations (1, 2). The bone marrow is usually hypercellular or at least normocellular and may contain increased numbers of immature cells. The diagnosis rests on the finding of characteristic morphologic abnormalities in the peripheral blood as well as in the marrow. Among the commonest abnormalities are asynchrony of nuclear and cytoplasmic maturation, ringed sideroblasts, nuclear budding or premature karyorrhexis of erythrocyte nuclei, hypogranulated myeloid precursors, hyposegmented or hypersegmented nuclei in neutrophils, and micromegakaryocytes or megakaryocytes with a single large nucleus...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
